

Summary of recommendations for the prevention of malaria by the Committee to Advise on Tropical Medicine and Travel (CATMAT)

Boggild A¹, Brophy J², Charlebois P³, Crockett M⁴, Geduld J⁵, Ghesquiere W⁶, McDonald P⁷, Plourde P⁸, Teitelbaum P⁹, Tepper M¹⁰, Schofield S¹¹ and McCarthy A (Chair)^{12*}

¹ University Health Network, Toronto General Hospital (Toronto, ON)

² Division of Infectious Diseases, Children's Hospital of Eastern Ontario (Ottawa, ON)

³ Internal Medicine, Canadian Forces Health Services Centre (Atlantic) (Halifax, NS)

⁴ Paediatrics and Child Health, University of Manitoba (Winnipeg, MB)

⁵ Infectious Disease Prevention and Control Branch, Public Health Agency of Canada (Ottawa, ON)

⁶ Infectious Diseases and Internal Medicine, University of British Columbia (Victoria, BC)

⁷ Therapeutic Products Directorate, Health Canada (Ottawa, ON)

⁸ Faculty of Medicine, University of Manitoba (Winnipeg, MB)

⁹ Riverside Travel Medicine Clinic (Ottawa, ON)

¹⁰ Communicable Disease Control Program, Directorate of Forces Health Protection (Ottawa, ON)

¹¹ Pest Management Entomology, Directorate of Forces Health Protection (Ottawa, ON)

¹² Tropical Medicine and International Health Clinic, Division of Infectious Disease, Ottawa Hospital General Campus (Ottawa, ON)

* Corresponding author: AMcCARTHY@Ottawahospital.on.ca

Abstract

Background: On behalf of the Public Health Agency of Canada, the Committee to Advise on Tropical Medicine and Travel (CATMAT) developed the *Canadian Recommendations for the Prevention and Treatment of Malaria Among International Travellers* for Canadian health care providers who are preparing patients for travel to malaria-endemic areas and treating travellers who have returned ill.

Objective: To provide guidelines on risk assessment and prevention of malaria

Methods: CATMAT reviewed all major sources of information on malaria prevention, as well as recent research and national and international epidemiological data, to tailor guidelines to the Canadian context. The evidence-based medicine recommendations were developed with associated rating scales for the strength and quality of the evidence.

Recommendations: Used together and correctly, personal protective measures (PPM) and chemoprophylaxis very effectively protect against malaria infection. PPM include protecting accommodation areas from mosquitoes, wearing appropriate clothing, using bed nets pre-treated with insecticide and applying topical insect repellent (containing 20%–30% DEET or 20% icaridin) to exposed skin. Selecting the most appropriate chemoprophylaxis involves assessment of the traveller's itinerary to establish his/her malaria risk profile as well as potential drug resistance issues. Antimalarials available on prescription in Canada include chloroquine (or hydroxychloroquine), atovaquone-proguanil, doxycycline, mefloquine and primaquine.

Introduction

Malaria is a serious infection caused by five different species of the genus *Plasmodium*: *falciparum*, *vivax*, *ovale*, *malariae* and *knowlesi*. Malaria is transmitted by the bite of infected female anopheline mosquitoes.

In 2009, 35% of Canadian travellers who went to a destination other than the United States visited a country that presented a risk of malaria, an increase of 131% from 2000 (1-2). Between September 2009 and September 2011, 94 cases of malaria were diagnosed among returned Canadian travellers (3).

According to the Centers for Disease Control and Prevention (CDC), malaria risk for travellers from the United States (4-6) varied as follows:

- Highest in west Africa and parts of Oceania;
- Moderate for other parts of Africa, parts of South America and South Asia;
- Lower for much of Central America, the Caribbean, Mexico and other parts of Asia and South America;
- Minimal in urban centres of southeast Asia and Central and South America, and in large resort areas in the Caribbean and Mexico.

The Committee to Advise on Tropical Medicine and Travel (CATMAT) provides the Public Health Agency of Canada with ongoing and timely medical, scientific and public health advice relating to tropical disease and health risks associated with international travel. This is a summary of the CATMAT *Canadian Recommendations for the Prevention and Treatment of Malaria Among International Travellers*, developed for Canadian health care providers who are preparing patients for travel to malaria-endemic areas and treating travellers who have returned ill (7). These guidelines include a full description of the recommendations on risk assessment and prevention of malaria, a disease that is still uncommon in Canada.

Methods

The Malaria Subcommittee, a working group of CATMAT, developed the guidelines. Each member is a volunteer, and none declared a relevant conflict of interest. Each chapter was updated by one to two members of the subcommittee and reviewed and approved by the full membership of CATMAT. The update was based on a thorough review of the literature. In addition, the Malaria Subcommittee reviewed all major sources of information on malaria prevention and treatment, including the World Health Organization (8), Centers for Disease Control and Prevention (CDC) (6) and the Health Protection Agency Advisory Committee on Malaria Prevention (9). The Malaria Subcommittee reviewed recent research, and national and international epidemiological data in order to tailor the recommendations to the Canadian context. Influencing factors include drug licensure, Canadian-specific travel patterns and related malaria epidemiology, and the anticipated values and preferences of travellers and health care providers. The evidence-based medicine recommendations for prevention of malaria were developed with associated rating scales for the strength and quality of the evidence.

CATMAT has taken into consideration both the need for protection and the potential for adverse effects of chemoprophylaxis. The guidelines also emphasize the varying degrees of endemicity in different regions. The health care provider should be properly informed to be able to provide appropriate guidance for the individual traveller.

Recommendations

The evidence-based CATMAT recommendations for malaria prevention are summarized in **Table 1**. A discussion of some of the key recommendations follows.

Table 1: Evidence-based medicine recommendations for prevention of malaria

Recommendation	EBM rating ¹
1. Properly used malaria chemoprophylaxis is very effective (6).	A I
2. Travellers should receive expert advice on malaria risks and strategies to avoid mosquitoes (10).	B III
3. A detailed review of the travel itinerary to determine the expected level of malaria endemicity and duration of exposure is essential to provide an accurate risk assessment for travellers (6,10,11).	B III
4. An assessment of the traveller's health and risk tolerances is also important in making malaria prevention recommendations.	B III
5. It is very important to adhere to recommended malaria prevention practices (e.g. use of chemoprophylaxis and PPM) (12-22).	B III
6. Chloroquine (Aralen [®]) or hydroxychloroquine (Plaquenil [®]) is the drug of choice for travellers to areas with chloroquine-sensitive malaria (23).	A I
7. Atovaquone-proguanil, doxycycline or mefloquine is the drug of choice for travellers to areas with chloroquine-resistant or mefloquine-sensitive malaria (12-14,24-27).	A I
8. Atovaquone-proguanil and doxycycline are the drugs of choice for travellers to areas with mefloquine-resistant malaria.	A I
9. Primaquine is recommended for malaria chemoprophylaxis for travellers to regions with chloroquine resistance who are not willing or able to use atovaquone-proguanil, doxycycline or mefloquine.	A I
10. Standby malaria treatment with atovaquone-proguanil or quinine and doxycycline is recommended for travellers who are more than a day away from malaria diagnostic help.	C III
11. Doxycycline is an antibiotic and should never be co-administered with any live, oral bacterial vaccines. Vaccination with live oral typhoid or cholera vaccines should be completed at least three days before the first dose of chloroquine, atovaquone-proguanil or mefloquine.	B III
12. Concurrent use of chloroquine interferes with antibody response to intradermal administration of human diploid cell rabies vaccine. If intradermal rabies vaccine is administered to someone taking chloroquine, it is recommended that post-vaccine rabies antibodies be obtained to verify an adequate immunologic response.	B III
13. Use insecticide-treated bed nets.	A I
14. Use topical repellents on exposed areas of skin to prevent arthropod bites and to reduce the risk of exposure to malaria-carrying mosquitoes.	A I
15. Products registered in Canada that contain 20%–30% DEET (<i>N,N</i> -Diethyl- <i>meta</i> -toluamide) or 20% icaridin should be the first choice for Canadian travellers.	A II
16. Products that contain <i>p</i> -menthane-3,8-diol (a chemical originally derived from the lemon eucalyptus plant) and that are registered in Canada should be considered second-choice topical repellents.	A II
17. Other active ingredients currently registered in Canada (e.g. citronella and soybean oil) are either not widely available and/or do not provide sufficiently long protection times against bites. These products are <i>not</i> recommended for protecting travellers against the bites of vectors.	E II
18. Protect work and accommodation areas against mosquitoes by using screening on doors, windows and eaves (the open area between the roof and wall), eliminating holes in roofs and walls, and closing other gaps around a building.	B I

Recommendation	EBM rating ¹
19. Wear insecticide-treated clothing.	B II
20. Wear appropriate clothing (e.g. full-length, loose-fitting and light-coloured clothing with sleeves rolled down and pants tucked into socks or boots).	B III
21. Do not use/rely on other insecticide-based approaches, such as insecticide coils that are burned, insecticide vaporizers, aerosols and space sprays, and insecticide-treated bed sheets.	E III
22. PPM that are either ineffective or that have not been convincingly shown to be efficacious against arthropod vectors and related diseases are <i>not recommended</i> . These include electronic (ultrasonic) devices; wristbands, neckbands and ankle bands impregnated with repellents; electrocuting devices (“bug zappers”); odour-baited mosquito traps; <i>Citrosa</i> plant (geranium houseplant); orally administered vitamin B1; and skin moisturizers that do not contain an approved repellent active ingredient.	E II

¹ EBM = Evidence based medicine. The EBM ratings are as follows:

Strength of recommendation:

- A = Good evidence to support a recommendation for use
- B = Moderate evidence to support a recommendation for use
- C = Poor evidence to support a recommendation for or against use
- D = Moderate evidence to support a recommendation against use
- E = Good evidence to support a recommendation against use

Quality of evidence:

- I = Evidence from at least one properly randomized, controlled trial
- II = Evidence from at least one well-designed clinical trial without randomization; from cohort or case-controlled analytic studies, preferably from more than one centre; from multiple time series; or from dramatic results in uncontrolled experiments
- III = Evidence from opinions of respected authorities on the basis of clinical experience, descriptive studies, or reports of expert committees

Risk assessment

CATMAT suggests a two-component process for malaria risk assessment: an exposure assessment and a host assessment.

An **exposure assessment** evaluates the probability of being bitten by infected mosquitoes. It takes three factors into account:

- Expected level(s) of endemicity in the travel itinerary;
- Presence/predominance of *P. falciparum*;
- Duration of exposure.

A **host assessment** evaluates the traveller’s health in relation to the potential hazard(s) of clinical malaria and the indications for specific malaria chemoprophylactic agents while taking into account personal preferences regarding risk management. Factors to consider include the following:

- General health of the traveller;
- Drug–drug interactions;
- Likelihood of access to appropriate medical care;
- Risk tolerance and individual preferences.

The completed risk assessment can be used to decide whether to use malaria chemoprophylaxis and which chemoprophylactic agent to prescribe:

- If malaria risk is minimal and the incidence of *P. falciparum* is nil or very low, CATMAT recommends using chemoprophylaxis (with PPM) *for a stay longer than two weeks*.
- If malaria risk is minimal and the incidence of *P. falciparum* is higher, CATMAT recommends *chemoprophylaxis (with PPM) for a stay longer than one week*.

Travellers who decide not to use chemoprophylaxis have a higher risk of malaria but lower risk of chemoprophylaxis-associated adverse effects; the opposite is true for those who decide to use it.

A country-by-country characterization of malaria transmission areas is available in the complete guidelines (7). The **Appendix** provides chemoprophylaxis recommendations for the top 25 destinations with risk of malaria transmission that are visited by Canadians.

Personal protective measures

- The risk of being bitten by a mosquito can be reduced by using physical and/or chemical barriers.
- Physical barriers:
 - Screening on doors, windows, eaves and other gaps in the building (28-30);
 - Bed nets treated with insecticide (31-33);
 - Full-length, loose-fitting and light-coloured clothing (clothes can also be treated with insecticide).
- Chemical barriers repel mosquitoes and/or kill them (34,35). The main chemical modalities currently available are topical insect repellents for use on exposed skin and insecticides that impregnate bed nets and clothing (36-40).
 - Topical repellents should contain 20%–30% DEET or 20% icaridin.
 - Alternatively, second-choice topical repellents are those containing *p*-menthane-3,8-diol that are registered in Canada.

Travellers should also be encouraged to plan activities during periods when risk is reduced (e.g. during the daytime where the principal vectors are active in the evening) and to visit areas where transmission is less likely (e.g. urban centres, highland areas > 2000 m/6500 ft).

Chemoprophylaxis

Prescribing antimalarial drugs

Prescribe antimalarial chemoprophylaxis only after completing an individual risk assessment. For detailed descriptions of chemoprophylaxis and of chemotherapy see Chapter 8 of the *Canadian Recommendations for the Prevention and Treatment of Malaria Among International Travellers* (7). Selecting the most appropriate chemoprophylactic agent involves the following:

1. Evaluate the traveller's exact travel itinerary to determine his or her malaria risk profile.
2. Review the advantages and disadvantages of different regimens:
 - Take into account the traveller's health status, other medications and the risks and character of adverse drug effects.
 - Consider only those medications that are least likely to exacerbate any past or present medical problem(s).
3. Present all the available options to the traveller and, unless any medication is contraindicated, let travellers choose which first-line malaria chemoprophylactic regimens they prefer.
4. Select the appropriate dosage of the medication:
 - Explain the dosing schedule, including the need to take the drug before, during and after visiting the area of risk, the desirability of taking the drug at the same time each day and advice on whether the prescribed medication should be taken with food, as well as any precautions regarding drug-specific side effects (e.g. sun exposure with doxycycline) (41-47).
5. Suggest a drug trial to check for possible medication-associated adverse reactions.
6. Discuss strategies to change medication if serious adverse effects arise during travel.
 - Advise the traveller to continue to take the prescribed malaria medication if it is well tolerated regardless of negative anecdotes about it. Long-term use of the chemoprophylactic agents currently recommended in Canada does not result in additional risks of severe adverse effects.

Discuss the importance of seeking medical advice urgently if a fever develops while the traveller is in a malaria-endemic area or within one year of leaving.

Selecting antimalarial drugs for specific regions of drug resistance

Monitor appropriate sources (e.g. Public Health Agency of Canada, CDC, ProMED) to stay abreast of new information about malaria risks before giving pre-travel care. This is especially relevant for minimal-risk regions because changes may directly affect the recommendations for chemoprophylaxis.

Table 2: Selecting antimalarial drugs for specific regions of drug resistance

Area/region (6,48-50)	Drugs of choice
Chloroquine-sensitive regions: Haiti, the Dominican Republic, Central America north of the Panama Canal, parts of Mexico, parts of South America, north Africa, parts of the Middle East, and west/central China	Chloroquine (Aralen [®]) Hydroxychloroquine (Plaquenil [®]) is an acceptable equivalent alternative (51), as are the three drugs used in chloroquine-resistant areas (see below).
Chloroquine-resistant regions: Most of sub-Saharan Africa, South America, Oceania and Asia. See below for regions that are both chloroquine- and mefloquine-resistant.	Atovaquone-proguanil (41,42,44-47,52) Doxycycline (41,42,44-47,52) Mefloquine (41,42,44-47,52)
Chloroquine- and mefloquine-resistant regions: Various countries in Asia, Africa and the Amazon basin. However, it is a significant problem only in rural, wooded regions where Thailand borders with Myanmar (Burma), Cambodia and Laos, and in southern Vietnam.	Atovaquone-proguanil (44,53,54) Doxycycline (44,53,54)

Note: See the **Appendix**, 'Malaria risk and recommended chemoprophylaxis in top 25 malaria-endemic travel destinations visited by Canadians in 2012', or a more complete list in the *Canadian Recommendations for the Prevention and Treatment of Malaria among International Travellers* (7).

Discontinuing antimalarial drugs

Fatal malaria has occurred in travellers who have discontinued all chemoprophylaxis or effective chemoprophylaxis in favour of something less protective (24,51,55,56). Discontinuation of all chemoprophylaxis is NOT a reasonable option.

Other travellers and/or health care providers may suggest changing or stopping antimalarial medication. For the most part, such advice should be ignored or questioned. Medications used in other areas of the world may be less effective, may be associated with serious adverse effects or may not be manufactured to Canadian standards. Examples include proguanil alone (Paludrine[®]), pyrimethamine (Daraprim[®]), dapsone-pyrimethamine (Maloprim[®]) and mefloquine-sulfadoxine-pyrimethamine (Fansimef[®]).

However, if the traveller experiences significant adverse events because of the chemoprophylactic agent, the medication can be changed, especially if the advice is provided by a health care provider (preferably the one who provided the initial advice).

Adherence to chemoprophylaxis

The reasons for non-adherence include lack of knowledge that malaria was a threat; fear of or past experience with adverse effects of chemoprophylactic agents; the false belief that prior malaria infections have conferred long-term immunity; the cost of medications; and confusion arising from contradictory recommendations. However, there is little information on how to enhance adherence.

Non-adherence to or suboptimal use of chemoprophylaxis and other preventive interventions is common, particularly among backpacking travellers; immigrants returning to visit their country of origin; people travelling for

longer than one month; travellers aged 40 years or less; and those using chemoprophylactic agents that must be taken daily (12-21,23,25-27,57).

Health care providers themselves need to be properly informed to be able to provide appropriate guidance (58). Travellers who use one qualified information source, such as a family physician trained in travel medicine, are significantly more likely to be compliant with malaria prophylaxis than those who collect information from multiple sources that could contradict each other (58,59).

Summary

A summary of the key changes made to the 2014 Guidelines are noted in **Table 3**.

Table 3: Summary of key additions and changes to the 2014 Guidelines pertaining to prevention of malaria (7)

Additions	
1.	The addition of a length-of-stay threshold for use of malaria chemoprophylaxis so that health care providers can better tailor individualized risk assessments (see Chapter 2).
2.	A new insect repellent, 20% icaridin, is recognized as an equivalent to DEET as a first-line choice for mosquito repellent (see Chapter 3).
3.	The guidelines have been expanded for populations requiring special attention – children, migrants, expatriates and travellers visiting friends and relatives, women who are pregnant or breastfeeding, and travellers with co-morbidities (Chapter 5).
4.	A new “Malaria Card” that can be given to travellers with information about their malaria chemoprophylaxis and an important reminder to seek medical attention in the event of a fever illness after travel.
Changes	
1.	Chapter 4, “Prevention – Chemoprophylaxis Regimens,” has been refined to make it easier to navigate the drug choices available. These changes include a simplified, step-wise approach to selecting malaria prophylaxis; comprehensive listings of medications and malaria risk by country/area in tabular form; and expanded explanation of the differences in approaches to malaria prophylaxis in other jurisdictions.
2.	Chapter 8, “Drugs for the Prevention and Treatment of Malaria,” includes an update on primaquine use for malaria prophylaxis and prevention; additional up-to-date information on pediatric dosing of atovaquone/proguanil; and general updates to Table 8.11: Drugs (generic and trade name) for the treatment and prevention of malaria. Revisions have also been made to the following sub-sections related to malaria prevention: chloroquine and mefloquine (with increased emphasis on selection or avoidance of this drug according to individual tolerability).

Acknowledgements

CATMAT acknowledges and appreciates the contribution of Joanna Odrowaz, Elspeth Payne to the development of the summaries and Manisha Kulkarni for her contribution to the statement.

CATMAT Members: Boggild A, Brophy J, Bui YG, Crockett M, Ghesquiere W, Greenaway C, Henteleff A, Libman M, Teitelbaum P and McCarthy A (Chair).

Liaison members: Hui C (Canadian Paediatric Society) and Gershman M (US Centers for Disease Control and Prevention).

Ex-officio members: Marion D (Canadian Forces Health Services Centre, Department of National Defence), McDonald P (Division of Anti-Infective Drugs, Health Canada), Schofield S (Directorate of Force Health Protection, Department of National Defence), and Tepper M (Directorate of Force Health Protection, Department of National Defence).

Member Emeritus: Jeanes CWL.

Conflict of interest

There are no conflicts of interest to declare.

Funding

This work was supported by the Public Health Agency of Canada.

References

- (1) World Health Organization. World Malaria Report 2012. 2012:1-195.
- (2) Geduld J, Bryson M, Straight-Caron T. Canadian Trends of International Travel and Risk of Malaria Exposure, 12th Conference of the International Society of Travel Medicine, May 8-12, 2011, Boston, US. 2011.
- (3) Boggild A, Geduld J, Libman M, Ward B, McCarthy A, Doyle P, Ghesquiere W, Vincelette J, Kuhn S, Freedman D, Kain K. Travel-acquired infections and illnesses in Canadians: surveillance report from CanTravNet surveillance data, 2009-2011. *Open Med* 2014;8(1).
- (4) Mali S, Tan KR, Arguin PM. Division of Parasitic Diseases and Malaria, Center for Global Health. Centers for Disease Control and Prevention. Malaria surveillance--United States, 2009. *MMWR Surveill Summ* 2011 Apr;60(3):1-15.
- (5) Mali S, Steele S, Slutsker L, Arguin P. Malaria surveillance--United States, 2008. *MMWR* 2010;59(7):1-15.
- (6) Centers for Disease Control and Prevention (CDC). CDC Health Information for International Travel 2012. New York: Oxford University Press; 2012.
- (7) Committee to Advise on Tropical Medicine and Travel. Canadian Recommendations for the Prevention and Treatment of Malaria (in press). <http://publications.gc.ca/site/eng/463465/publication.html>
- (8) World Health Organization. International Travel and Health. Geneva, Switzerland: World Health Organization; 2012.
- (9) Bradley D, Bannister B, Health Protection Agency Advisory Committee on Malaria Prevention for UK Travellers. Guidelines for malaria prevention in travellers from the United Kingdom for 2003. *Commun Dis Public Health* 2003;6(3):180-199.
- (10) Steffen R, deBernardis C, Banos A. Travel epidemiology--a global perspective. *Int J Antimicrob Agents* 2003;21(2):89-95.
- (11) Leder K, Black J, O'Brien D, Greenwood Z, Kain KC, Schwartz E, et al. Malaria in travelers: a review of the GeoSentinel surveillance network. *Clin Infect Dis* 2004 Oct;39(8):1104-1112.
- (12) Chatterjee S. Compliance of malaria chemoprophylaxis among travelers to India. *J Travel Med* 1999 Mar;6(1):7-11.
- (13) Laver SM, Wetzels J, Behrens RH. Knowledge of malaria, risk perception, and compliance with prophylaxis and personal and environmental preventive measures in travelers exiting Zimbabwe from Harare and Victoria Falls International airport. *J Travel Med* 2001 Nov-Dec;8(6):298-303.
- (14) Banerjee D, Stanley PJ. Malaria chemoprophylaxis in UK general practitioners traveling to South Asia. *J Travel Med* 2001 Jul-Aug;8(4):173-175.
- (15) Lobel HO, Baker MA, Gras FA, Stennies GM, Meerburg P, Hiemstra E, et al. Use of malaria prevention measures by North American and European travelers to East Africa. *J Travel Med* 2001 Jul-Aug;8(4):167-172.

- (16) Leonard L, VanLandingham M. Adherence to travel health guidelines: the experience of Nigerian immigrants in Houston, Texas. *J Immigr Health* 2001 Jan;3(1):31-45.
- (17) Morgan M, Figueroa-Munoz JI. Barriers to uptake and adherence with malaria prophylaxis by the African community in London, England: focus group study. *Ethn Health* 2005 Nov;10(4):355-372.
- (18) Alon D, Shitrit P, Chowers M. Risk behaviors and spectrum of diseases among elderly travelers: a comparison of younger and older adults. *J Travel Med* 2010 Jul-Aug;17(4):250-255.
- (19) Toovey S, Moerman F, van Gompel A. Special infectious disease risks of expatriates and long-term travelers in tropical countries. Part I: malaria. *J Travel Med* 2007 Jan-Feb;14(1):42-49.
- (20) Baggett HC, Graham S, Kozarsky PE, Gallagher N, Blumensaadt S, Bateman J, et al. Pretravel health preparation among US residents traveling to India to VFRs: importance of ethnicity in defining VFRs. *J Travel Med* 2009 Mar-Apr;16(2):112-118.
- (21) Piyaphanee W, Wattanagoon Y, Silachamroon U, Mansanguan C, Wichianprasat P, Walker E. Knowledge, attitudes, and practices among foreign backpackers toward malaria risk in southeast Asia. *J Travel Med* 2009 Mar-Apr;16(2):101-106.
- (22) Abraham C, Clift S, Grabowski P. Cognitive predictors of adherence to malaria prophylaxis regimens on return from a malarious region: a prospective study. *Soc Sci Med* 1999;48(11):1641-54.
- (23) Queyriaux B, Texier G, Ollivier L, Galois-Guibal L, Michel R, Meynard JB, et al. *Plasmodium vivax* malaria among military personnel, French Guiana, 1998-2008. *Emerg Infect Dis* 2011 Jul;17(7):1280-1282.
- (24) Kain KC, MacPherson DW, Kelton T, Keystone JS, Mendelson J, MacLean JD. Malaria deaths in visitors to Canada and in Canadian travellers: a case series. *CMAJ* 2001 Mar;164(5):654-659.
- (25) Landry P, Iorillo D, Darioli R, Burnier M, Genton B. Do travelers really take their mefloquine malaria chemoprophylaxis? Estimation of adherence by an electronic pillbox. *J Travel Med* 2006 Jan-Feb;13(1):8-14.
- (26) Molle I, Christensen KL, Hansen PS, Dragsted UB, Aarup M, Buhl MR. Use of medical chemoprophylaxis and antimosquito precautions in Danish malaria patients and their traveling companions. *J Travel Med* 2000 Sep-Oct;7(5):253-258.
- (27) Ollivier L, Michel R, Carlotti MP, Mahe P, Romand O, Todesco A, et al. Chemoprophylaxis compliance in a French battalion after returning from malaria-endemic area. *J Travel Med* 2008 Sep-Oct;15(5):355-357.
- (28) Lindsay SW, Jawara M, Paine K, Pinder M, Walraven GEL, Emerson PM. Changes in house design reduce exposure to malaria mosquitoes. *Trop Med Int Health* 2003;8(6):512-517.
- (29) Lindsay SW, Emerson PM, Charlwood JD. Reducing malaria by mosquito-proofing houses. *Trends Parasitol* 2002;18(11):510-514.
- (30) Njie M, Dilger E, Lindsay S, Kirby M. Importance of eaves to house entry by anopheline, but not culicine, mosquitoes. *J Med Entomol* 2009;46(3):505-10.
- (31) Christophers SR. Mosquito repellents; being a report of the work of the Mosquito Repellent Inquiry, Cambridge, 1943-5. *J Hyg* 1947;45(2):176-231.
- (32) Schoepke A, Steffen R, Gratz N. Effectiveness of personal protection measures against mosquito bites for malaria prophylaxis in travelers. *J Travel Med* 1998;5(4):188-192.
- (33) Joy RJT. Malaria in American troops in the South and Southwest Pacific in World War II. *Med Hist* 1999;43(02):192-207.
- (34) Maia M, Moore S. Plant-based insect repellents: a review of their efficacy, development and testing. *Malar J* 2011;10:S11.

- (35) Moore SJ, Debboun M. History of insect repellents. In: Debboun M, Francis S, Strickman DA, editors. Insect repellents: principles, methods and uses. 1st ed.: CRC Press; 2006. p. 3-29.
- (36) Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. *Cochrane Database Syst Rev* 2004;2(CD000363).
- (37) Schreck CE, Posey K, Smith D. Durability of permethrin as a potential clothing treatment to protect against blood-feeding arthropods. *J Econ Entomol* 1978;71(3):397-400.
- (38) Schreck CE, Haile DG, Kline DL. The effectiveness of permethrin and deet, alone or in combination, for protection against *Aedes taeniorhynchus*. *Am J Trop Med Hyg* 1984;33(4):725-730.
- (39) Vaughn MF, Meshnick SR. Pilot study assessing the effectiveness of long-lasting permethrin-impregnated clothing for the prevention of tick bites. *Vector Borne Zoonotic Dis* 2011;11(7):869-875.
- (40) Soto J, Medina F, Dember N, Berman J. Efficacy of permethrin-impregnated uniforms in the prevention of malaria and leishmaniasis in Colombian soldiers. *Clin Infect Dis* 1995 Sep;21(3):599-602.
- (41) Shanks GD, Kremsner PG, Sukwa TY, Van Der Berg JD, Shapiro TA, Scott TR, et al. Atovaquone and proguanil hydrochloride for prophylaxis of malaria. *J Travel Med* 1999;6(Suppl 1):S21-S27.
- (42) Sanchez J, DeFraitres R, Sharp T, Hanson R. Mefloquine or doxycycline prophylaxis in US troops in Somalia. *Lancet* 1993;341(8851):1021-12.
- (43) Koren G, Matsui D, Bailey B. DEET-based insect repellents: safety implications for children and pregnant and lactating women. *CMAJ* 2003;169(3):209-12.
- (44) Ohrt C, Richie T, Widjaja H, Shanks G, Fitriadi J, Fryauff D, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 1997;126(12):963-72.
- (45) Weiss W, Oloo A, Johnson A, Koech D, Hoffman S. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. *J Infect Dis* 1995;171(6):1569-75.
- (46) Sukwa T, Mulenga M, Chisdaka N, Roskell N, Scott T. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. *Am J Trop Med Hyg* 1999;60(4):521-5.
- (47) Shanks G, Gordon D, Klotz F, Aleman G, Oloo A, Sadie D, et al. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for *Plasmodium falciparum* malaria. *Clin Infect Dis* 1998;27(3):494-9.
- (48) Centers for Disease Control and Prevention (CDC). *CDC Health Information for International Travel 2014*. New York: Oxford University Press; 2013.
- (49) Wongsrichanalai C, Sirichaisinthop J, Karwacki JJ, Congpuong K, Miller RS, Pang L, et al. Drug resistant malaria on the Thai-Myanmar and Thai-Cambodian borders. *Southeast Asian J Trop Med Public Health* 2001 Mar;32(1):41-49.
- (50) Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. *Lancet Infect Dis* 2002 Apr;2(4):209-218.
- (51) Newman R, Parise M, Barber A, Steketee R. Malaria-related deaths among U.S. travelers, 1963-2001. *Ann Intern Med* 2004;141(7):547-55.
- (52) Lell B, Luckner D, Ndjave M, Scott T, Kremsner P. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. *Lancet* 1998;351(9104):709-13.

- (53) Camus D, Djossou F, Schilthuis HJ, Hogh B, Dutoit E, Malvy D, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. *Clin Infect Dis* 2004 Jun;38(12):1716-1723.
- (54) Krudsood S, Patel SN, Tangpukdee N, Thanachartwet W, Leowattana W, Pornpininworakij K, et al. Efficacy of atovaquone-proguanil for treatment of acute multidrug-resistant *Plasmodium falciparum* malaria in Thailand. *Am J Trop Med Hyg* 2007 Apr;76(4):655-658.
- (55) Humar A, Sharma S, Zoutman D, Kain KC. Fatal falciparum malaria in Canadian travellers. *CMAJ* 1997 April;156(8):1165-1167.
- (56) Centers for Disease Control and Prevention (CDC). Malaria deaths following inappropriate malaria chemoprophylaxis--United States, 2001. *MMWR Morb Mortal Wkly Rep* 2001 Jul;50(28):597-599.
- (57) Pistone T, Ezzedine K, Gaudin AF, Hercberg S, Nachbaur G, Malvy D. Malaria prevention behaviour and risk awareness in French adult travellers. *Travel Med Infect Dis* 2010 Jan;8(1):13-21.
- (58) Ropers G, Du Ry van Beest Holle M, Wichmann O, Kappelmayer L, Stuben U, Schonfeld C, et al. Determinants of malaria prophylaxis among German travelers to Kenya, Senegal, and Thailand. *J Travel Med* 2008 May-Jun;15(3):162-171.
- (59) Held TK, Weinke T, Mansmann U, Trautmann M, Pohle HD. Malaria prophylaxis: identifying risk groups for non-compliance. *Q J Med* 1994 Jan;87(1):17-22.
- (60) Institut de médecine sociale et préventive de l'Université de Zurich. Santé-voyages: Vaccinations et mesures antipaludiques 2010. 2010; Available at: <http://www.bag.admin.ch/themen/medizin/00682/00685/03062/index.html?lang=fr>. Accessed November 18, 2010.
- (61) World Health Organization. International Travel and Health, Country List. 2011; Available at: <http://www.who.int/ith/en/>.
- (62) Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit (DTG). Empfehlungen zur Malariavorbeugung. 2011; Available at: http://www.dtg.org/uploads/media/Malaria_2011.pdf. Accessed June 12, 2011.
- (63) Office fédéral de la santé publique, Confédération suisse, Division maladies transmissibles. Paludisme (malaria) – mise à jour 2010. *OFSP* 2010;19:506-8.
- (64) Smittskyddsinstitutet. Rekommendationer för malariaprofylax 2010. 2010; Available at: <http://www.folkhalsomyndigheten.se/publicerat-material/publikationer/?topic=smittskydd-och-sjukdomar>. Accessed November 24, 2010.
- (65) International Association for Medical Assistance to Travellers 2011. World Malaria Risk Chart. 2011; Available at: http://www.iamat.org/disease_details.cfm?id=140.
- (66) Haut Conseil de la santé publique. Recommandations sanitaires pour les voyageurs 2011 (à l'attention des professionnels de santé). 2011; Available at: http://opac.invs.sante.fr/doc_num.php?explnum_id=7068. Accessed June 1, 2011.
- (67) Statistics Canada. International Travel Survey: Canadian Residents 2012 (Custom Extract).

Appendix

Appendix: Malaria risk and recommended chemoprophylaxis in top 25 malaria-endemic travel destinations visited by Canadians in 2012 (6, 60-67)

Country	Malaria transmission areas ⁽²⁻⁴⁾	Chemoprophylaxis recommended by CATMAT ^{*(2-9)}	Season ^(3,4)	<i>Plasmodium falciparum</i> ⁽²⁻⁴⁾ , %
1 Mexico	Minimal or no malaria transmission in major resort areas on the coasts, including the city of Acapulco or along the Mayan Riviera, including the cities of Cancún, Cozumel, and Playa del Carmen. None along the border with the United States.	None.	Year-round	0
	Little malaria transmission in the states of Jalisco, Quintana Roo, Sonora and Tabasco.	Use PPM.		
	Moderate risk in parts of the states of Chiapas and Oaxaca.	Chloroquine.		
	Low risk in rural areas of the states of Nayarit, Sinaloa, Chihuahua, and Durango.	Chloroquine for stays > 1 week; chloroquine or PPM alone for stays of ≤ 1 week.		
2 Dominican Republic	Little to no malaria transmission in the resort areas of Romana and Samaná and the cities of Santo Domingo, Santiago, and Puerto Plata.	None; use PPM.	Year-round	100
	Some transmission has previously occurred in La Altagracia province, including resort areas such as Punta Cana.	In the absence of any further outbreaks in La Altagracia, PPM alone for resorts in that province. Seek medical attention if a fever develops.		
	Rural areas, with the highest risk in the provinces of Dajabón, Elias Piña, and San Juan bordering Haiti.	Chloroquine.		
3 China	No malaria transmission in urban areas or northern China.	None.	n/a	n/a
	Limited transmission of <i>P. vivax</i> malaria occurs in the southern provinces and some central provinces, including Anhui, Ghuizhou, Henan, Hubei, and Jiangsu.	For travellers visiting major cities and making daytime excursions into the countryside or on Yangtze river cruises: none; use PPM.	Year-round	9
	The risk of contracting malaria in central China is small.	For those travelling extensively in or through rural southern China: chloroquine.		
	Transmission of <i>P. falciparum</i> malaria occurs in the province of Yunnan and, to a lesser extent, in the province of Hainan. <i>P. falciparum</i> resistance to chloroquine and sulfadoxine-pyrimethamine reported.	ATQ-PG, DOXY or MFQ.		
	<i>P. falciparum</i> resistance to mefloquine reported in the province of Yunnan in the areas bordering Burma (Myanmar).	ATQ-PG or DOXY.		
4 India	No malaria transmission at elevations > 2000 m in parts of the states of Himachal Pradesh, Jammu and Kashmir, and Sikkim.	None.	n/a	n/a
	All other areas - including most urban areas such as Bombay (Mumbai) and Delhi. Risk is lower in most of the southernmost regions of India.	ATQ-PG, DOXY or MFQ.	Year-round	> 40
	Risk is low in central urban areas of Agra and Bangalore.	PPM alone can be considered for stays of <1		

			week in central urban areas of Delhi, Agra and Bangalore.		
5	Costa Rica	Little to no risk of malaria transmission in most of the country, with exception noted below. No malaria transmission in the city of Limón (Puerto Limón).	None; use PPM.	Year-round	Predominantly <i>P vivax</i>
		Limón province (except the city of Limón), mostly in the canton of Matina.	Chloroquine.		
6	Thailand	No malaria transmission in cities, including Bangkok, Chiang Mai, Chiang Rai, Pattaya, Koh Samui, Phang Nga, Town of Phuket and Koh Phangan, or in major tourist resorts.	None.	n/a	n/a
		Rural forested areas near the borders with Cambodia, Burma (Myanmar) and Laos. Rural forested areas in districts of Phang Nga and Phuket. Some islands have malaria risk. Mefloquine resistance reported.	ATQ-PG or DOXY.	Year-round	50–75
7	Philippines	Little to no malaria transmission in urban areas or on islands not listed below.	None; use PPM.	Year-round	70–80
		Rural areas at elevations < 600 m on islands of Basilu, Luzon, Mindanao, Mindoro, Palawan, Sulu (Jolo) and Tawi-Tawi.	ATQ-PG, DOXY or MFQ.		
8	South Africa	No malaria transmission in most of the country including the Garden Route and major cities.	None.	n/a	n/a
		Low-altitude areas in the provinces of Mpumalanga (including the Kruger National Park), Limpopo (formerly Northern), and north-eastern Kwa Zulu-Natal as far south as the Tugela River.	ATQ-PG, DOXY or MFQ.	Year-round (risk is highest from Oct–May)	90
9	Peru	No malaria risk at elevations > 2000 m, including the highland tourist areas (Machu Picchu, Lake Titicaca, and the cities of Arequipa, Cuzco, Puno) or in the cities of Lima and south of Lima including Moquegua, Nazca, and Tacna.	None.	n/a	n/a
		All areas < 2000 m (except cities listed above). This includes the cities of Puerto Maldonado and Iquitos. Most <i>P. falciparum</i> cases occur in the region of Loreto.	ATQ-PG, DOXY or MFQ.	Year-round	15
10	Turkey	No malaria transmission in western and northeastern parts of the country, including the common tourist destinations of the cities of Izmir and Istanbul and the Cappadocia region.	None.	n/a	n/a
		Limited malaria transmission in the southeastern part of the country.	Chloroquine for stays > 2 weeks; <i>chloroquine or PPM</i> alone for stays of ≤ 2 weeks.	May–Oct	Sporadically
11	Argentina	No malaria transmission in urban areas, Iguazu Falls, or provinces not listed below.	None.	n/a	n/a
		Rare in Misiones province along the border with Paraguay.	None; use PPM.	Oct–May	0
		Rural areas of northern Jujuy and Salta Province (along Bolivian border).	Chloroquine for stays > 2 weeks; <i>chloroquine or PPM</i> alone for stays of ≤ 2 weeks.		
12	Brazil	Little to no malaria transmission at Iguazu Falls; in the Pantanal region; in the cities of Brasília, Recife, Rio de Janeiro, São Paulo, and Salvador; or in other areas not listed below.	None; use PPM.	Year-round	15
		Areas at elevations < 900 m in most forested areas of the states of Acre, Amapá, Amazonas, Rondônia, Roraima and Tocantins	ATQ-PG, DOXY or MFQ.		

		(western part) and parts of states of Maranhão (western part), Mato Grosso (northern part), Pará (except Belém City) and Tocantins (western part). Transmission also occurs in some peripheral urban areas of - Boa Vista, Cruziero do Sul, Macapá, Manaus, Marabá, Pôrto Velho, Rio Branco, and Santarém.			
13	Belize	No malaria transmission in Belize City and islands frequented by tourists.	None.	n/a	n/a
		Low risk in Belize, Corozal, and Orange Walk Districts.	None; use PPM.	Year-round	0–5
		Moderate risk in Cayo, Stann Creek, and Toledo Districts.	Chloroquine.		
14	Ecuador	No malaria transmission at elevations > 1500 m, including Cuenca, Quito, and other cities and villages in the Andean highlands; in the city of Guayaquil or on the Galápagos Islands.	None.	n/a	n/a
		All other areas at elevations < 1500 m. Higher risk along the coast, in the north.	ATQ-PG, DOXY or MFQ.	Year-round	10
15	Colombia	No malaria transmission in urban areas, including Bogotá and vicinity and Cartagena; at elevations > 1600 m; or on the islands of San Andrés and Providencia in the Caribbean Sea.	None.	n/a	n/a
		Rural or jungle areas at elevations < 1600m.	ATQ-PG, DOXY or MFQ.	Year-round	35–40
16	Guatemala	No malaria transmission in urban areas or areas at elevations > 1500 m none in Guatemala City, Antigua, and Lake Atitlán.	None.	n/a	n/a
		Rural areas at elevations < 1500 m.	Chloroquine.	Year-round	3
17	Honduras	No malaria transmission - in the cities of Tegucigalpa and San Pedro Sula.	None.	n/a	n/a
		Risk is low in higher mountainous areas in the west where PPM can be considered.			
		Risk is high in departments of Gracias a Dios and Islas de la Bahía (Bay Islands), and moderate in Atlantida, Colon, Olancho, and Yoro.	Chloroquine.	Year-round	7
18	Vietnam	None in urban areas, Red River Delta and coastal plain of central Vietnam. Rare cases in Mekong Delta. The common coastal itinerary between Ho Chi Minh City and Hanoi with overnights mainly in urban areas does not typically require chemoprophylaxis.	Use PPM.	Year-round	50–90
		Rural areas, excluding those listed above. Risk in the town of Sapa in the hills to the northwest of Hanoi is lower; PPM can be considered for stays <1 week, particularly in the winter months.	ATQ-PG, DOXY or MFQ.		
		Mefloquine resistance reported in the southern part of the country in the provinces of Dac Lac, Gia Lai, Khanh Hoa (western part), Kon Tum, Lam Dong, Ninh Thuan (western part), Song Be, and Tay Ninh.	ATQ-PG or DOXY.		
19	Cambodia	No malaria transmission in the city of Phnom Penh and the area around Lake Tonlé Sap (Siem Reap). Negligible transmission in the tourist area of Angkor Wat and Siem Reap.	None; use PPM.	Year-round	86
		Mefloquine resistance is reported in the western provinces of Banteay Meanchey,	Doxycycline or atovaquone-proguanil.		

		Battambang, Koh Kong, Odder Meanchey, Pailin, Kampot, PreahVihear, Pursat, and Siemreap bordering Thailand.			
		All other areas.	ATQ-PG, DOXY or MFQ.		
20	Panama	Little to no malaria transmission in Panama City, the Canal zone, or regions not listed below.	None; use PPM.	Year-round	1
		Provinces and indigenous territories (comarcas) along the Caribbean coast and the borders with Costa Rica and Colombia: Bocas del Toro, Chiriquí, Colón, Ngöbe-Buglé, Panamá, and Veraguas.	Chloroquine for stays > 1 week; <i>chloroquine or PPM alone for stays of <1 week.</i>		
		Most transmission in provinces east of the Panama Canal toward the border with Colombia. <i>P. falciparum</i> resistance to chloroquine has been reported in Darién and Kuna Yala (San Blas).	ATQ-PG, DOXY or MFQ.		
21	Pakistan	All areas at elevations < 2000 m. Risk is due to both <i>P. vivax</i> and <i>P. falciparum</i> . Risk lower in the north, including Islamabad, especially during winter months because of cool temperatures.	ATQ-PG, DOXY or MFQ.	Year-round	30
22	Kenya	Little to no malaria transmission at elevations > 2500 m or in the city of Nairobi.	None; use PPM.	Year-round	85
		All areas at elevations < 2500 m, except the city of Nairobi.	ATQ-PG, DOXY or MFQ.		
23	Tanzania, United Republic of	All areas at elevations < 1800 m.	ATQ-PG, DOXY or MFQ.	Year-round	> 85
24	Indonesia	No malaria transmission in Jakarta Municipality, major metropolitan areas including Ubud, or major tourist resorts in Bali and Java.	None.	n/a	n/a
			In general, risk is higher in more easterly regions of Indonesia: in particular, the provinces of East Nusa Tenggara, Maluku, North Maluku, Papua (Irian Jaya) and West Papua. There is also risk on Lombok Island and the rural areas of Kalimantan Island (Borneo). There is a low risk of transmission in rural Java and Bali and sporadic cases reported among travellers to rural areas of Bali. In the other parts of the country, there is malaria risk in some districts.	ATQ-PG, DOXY or MFQ.	Year-round
25	Nicaragua	Little to no malaria transmission in departments not listed below.	None; use PPM.	Year-round	10
			Departments of Chinandega, León, Managua, and Matagalpa and the autonomous regions of Atlántico Norte (RAAN) and Atlántico Sur (RAAS).		

* Chemoprophylaxis is recommended only in the risk areas identified during the transmission season identified. Chemoprophylaxis should always be used in conjunction with PPM. ATQ-PG, atovaquone-proguanil; DOXY, doxycycline; MFQ, melfloquine